Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline laxative that works by drawing water into the colon, stimulating bowel evacuation.
## Primary Indications
Constipation, bowel preparation for procedures (e.g., colonoscopy, surgery).
## Adult Dosing
* **Constipation:** Typically 1 single-use enema (4.5 oz or approximately 133 mL) administered rectally.
* **Bowel Preparation:** One 4.5 oz (approximately 133 mL) dose administered rectally, usually the evening before the procedure, or as per specific protocol. A second dose may be administered several hours before the procedure.
## Pediatric Dosing
* **Ages 2-11 years:** One-half the adult dose (approximately 2.25 oz or 67 mL).
* **Under 2 years:** Contraindicated due to increased risk of severe adverse effects.
## Dose Adjustments
* **Renal Impairment:** Use with caution and consider alternative agents due to the risk of hyperphosphatemia and hypocalcemia.
* **Hepatic Impairment:** No specific dose adjustment, but caution is advised due to potential electrolyte imbalances.
## Contraindications
* Congenital megacolon, intestinal obstruction, Hirschsprung disease, appendicitis, rectal fissures, severe dehydration, patients with impaired renal function (especially moderate to severe), patients with heart failure or other conditions predisposing to fluid retention, patients with hyperphosphatemia or hypocalcemia, patients under 2 years of age.
* Concurrent use of other sodium phosphate products.
## Adverse Effects
Common: Abdominal cramping, bloating, nausea, vomiting, rectal irritation.
Serious: Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia, dehydration, cardiac arrhythmias, renal damage, seizures, loss of consciousness.
## Key Drug Interactions
* **Diuretics (especially thiazides and loop diuretics):** Increased risk of electrolyte imbalances (hypernatremia, hypokalemia, hypocalcemia, hyperphosphatemia).
* **ACE inhibitors/ARBs:** Increased risk of hyperkalemia and renal impairment.
* **NSAIDs:** Increased risk of renal impairment.
## Monitoring
* Electrolytes (sodium, potassium, phosphate, calcium) before and after use, especially in patients with risk factors for imbalance.
* Renal function (BUN, creatinine).
* Fluid status.
* Signs and symptoms of severe adverse effects.
## Clinical Pearls
* Ensure adequate hydration before and after administration.
* Administer slowly and retain for the duration recommended in product labeling (typically 5-15 minutes).
* Avoid if patient has any contraindications.
* Due to risks, other bowel preparation agents may be preferred, particularly in elderly, pediatric, or renally impaired patients.
***
*This information is intended for healthcare professionals. Always verify current prescribing information and institutional protocols before use.*
